MIP Diagnostics, a Leicester, UK-based life sciences startup that develops “plastic antibodies” for a variety of applications, received a £300k follow-on funding.
Mercia Fund Management made the investment. MIP Diagnostics, a spin-out from the University of Leicester, has appointed Jim Reid as chair to provide commercial expertise.
To company will use the funds to to build and scale its business.
Founded as a spin-out from the University of Leicester in March 2015 and led by CEO Dr Adrian Kinkaid, MIP Diagnostics develops plastic antibodies for a variety of applications. Its technology provides Molecular Imprinted Polymers (MIPs) to the diagnostic, pharmaceutical, biotechnology and chemical research industries.
The company has secured significant blue-chip partnership deals.